Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.67 |
| ▸ | F11 | P03951 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.60 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.60 |
| ▸ | PDE5A | O76074 | 1/20 | 0.60 |
| ▸ | HMGCR | P04035 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.60 |
| ▸ | FYN | P06241 | 1/20 | 0.60 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CA6 | P23280 | 1/20 | 0.60 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.60 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.60 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.60 |
| ▸ | TST | Q16762 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7642894 | 1.00 | PTPN1 (0.67) | PTPN1F11USP2CA1CA2 | |
| SCHEMBL18083458 | 1.00 | PTPN1 (0.67) | PTPN1F11USP2CA1CA2 | |
| SCHEMBL7144957 | 1.00 | PTPN1 (0.67) | PTPN1F11USP2CA1CA2 | |
| SCHEMBL7251000 | 1.00 | PTPN1 (0.67) | PTPN1F11USP2CA1CA2 | |
| SCHEMBL19479105 | 1.00 | PTPN1 (0.67) | PTPN1F11USP2CA1CA2 | |
| SCHEMBL3785587 | 1.00 | PTPN1 (0.67) | PTPN1F11USP2CA1CA2 | |
| SCHEMBL18068260 | 1.00 | PTPN1 (0.67) | PTPN1F11USP2CA1CA2 | |
| SCHEMBL16731442 | 1.00 | PTPN1 (0.67) | PTPN1F11USP2CA1CA2 | |
| SCHEMBL7642890 | 1.00 | PTPN1 (0.67) | PTPN1F11USP2CA1CA2 | |
| SCHEMBL17633988 | 1.00 | PTPN1 (0.67) | PTPN1F11USP2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177885-A1 | ENDOSOMAL CLEAVABLE LINKERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| CN-112094310-B | Glucosinolate sterol glycoside and glucosinolate stanol glycoside, and preparation method and application thereof | 南京师范大学 | 2022-05-03 | — | — | CN | disclosed |
| CN-112094310-A | Glucosinolate sterol glycoside and glucosinolate stanol glycoside, and preparation method and application thereof | 南京师范大学 | 2020-12-18 | — | — | CN | disclosed |
| US-20190211045-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | UNIV WASHINGTON (US) | 2019-07-11 | — | — | US | disclosed |
| US-10273260-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2019-04-30 | — | — | US | disclosed |
| WO-2018136620-A2 | ENDOSOMAL CLEAVABLE LINKERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| US-20170247401-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | WASHINGTON UNIVERSITY | 2017-08-31 | — | — | US | disclosed |
| US-9371350-B2 | Trehalose derivatives and pharmaceutical compositions for treating neurodegenerative diseases | POSTECH FOUNDATION (KR) | 2016-06-21 | — | — | US | disclosed |
| US-20150197538-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-16 | — | — | US | disclosed |
| US-20150025035-A1 | INOSITOL AND TREHALOSE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES COMPRISING THE SAME | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2015-01-22 | — | — | US | disclosed |
| WO-2013149580-A1 | TIMOSAPONIN COMPOUNDS | CHE CHIMING (CN) | 2013-10-10 | — | — | WO | disclosed |
| US-20110224423-A1 | INOSITOL AND TREHALOSE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES COMPRISING THE SAME | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2011-09-15 | — | — | US | disclosed |
| WO-2010011012-A1 | INOSITOL AND TREHALOSE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES COMPRISING THE SAME | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273260-B2 | Compounds and methods for treating bacterial infections | MMP8, ELANE, GUSB | PTPN1 4164/4885F11 2717/4885USP2 1428/4885 |
| US-20110224423-A1 | INOSITOL AND TREHALOSE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES COMPRISING THE SAME | HTT, TREH, ITPA | PTPN1 4132/4885F11 3718/4885USP2 2770/4885 |
| US-20150025035-A1 | INOSITOL AND TREHALOSE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES COMPRISING THE SAME | HTT, TREH, ITPA | PTPN1 4132/4885F11 3718/4885USP2 2770/4885 |
| US-20170247401-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, ELANE, GUSB | PTPN1 4164/4885F11 2717/4885USP2 1428/4885 |
| US-20190211045-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, ELANE, GUSB | PTPN1 4164/4885F11 2717/4885USP2 1428/4885 |
| US-20150197538-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, ELANE, GUSB | PTPN1 4164/4885F11 2717/4885USP2 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.